Hong Kong to consult on regulatory framework for in vitro diagnostics
This article was originally published in SRA
Hong Kong’s Department of Health is preparing a regulatory framework for in vitro diagnostic products that would enable the Medical Device Control Office to oversee the sector1,2.
You may also be interested in...
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.